Vox Markets talks to hVIVO chief executive Mo Khan on a year that saw the human challenge trial specialist beat previously upgraded Ebitda guidance and start 2024 with the company’s highest ever starting order book, laying a solid foundation for its next phase of growth. 0:29 Mo Khan talks through the highlights of hVIVO’s expectation-beating FY23 trading update. 1:28 How operational gearing is flowing through into a rapidly increasing Ebitda margin. 2:22 What’s behind the increase in the order book to a record £80m, including an expanded range of human challenge models and increasing contract sizes. 4:07 The outlook for 2024, including 90% of revenue already contracted and the opening of the Canary Wharf facility that expands the group’s revenue capacity to over £90m of annual revenue. 5:31 How the new facility will further support margin expansion. 6:03 Other ambitions in the short to medium term, including £100m revenue by 2028, driven both organically and through bolt-on acquisitions. 7:26 The introduction of a dividend policy and the cash generative qualities of the group that underpins it.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related